( BW)(MA-OXIGENE)(OXGN)(OXGN.ST) OXiGENE Participates in Cowen & Company 27th Annual Healthcare Conference Available via Webcast
WALTHAM, Mass.--(BUSINESS WIRE)--March 8, 2007--Regulatory News:
OXiGENE, Inc. (NASDAQ: OXGN) (STO: OXGN), a leading developer of
biopharmaceutical compounds to treat cancer and certain ophthalmologic
diseases, announced today that Dr. Richard Chin, its President and
Chief Executive Officer, will present at the Cowen & Company 27th
Annual Healthcare Conference at The Boston Marriott Copley Place Hotel
in Boston, MA. Dr. Chin will present on Tuesday, March 13, 2007 at
1:45pm ET.
A live and archived webcast of the presentation can be accessed at
www.oxigene.com or http://www.corporate-ir.net/ireye/
conflobby.zhtml?ticker=OXGN&item_id=1491184.
About OXiGENE, Inc.
OXiGENE is an emerging pharmaceutical company developing novel
small-molecule therapeutics to treat cancer and eye diseases. The
Company's major focus is the clinical advancement of drug candidates
that selectively disrupt abnormal blood vessels associated with solid
tumor progression and visual impairment. OXiGENE is dedicated to
leveraging its intellectual property position and therapeutic
development expertise to bring life saving and enhancing medicines to
patients.
Safe Harbor Statement
Certain statements in this news release may be considered"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Any or all of the
forward-looking statements in this press release may turn out to be
wrong. They can be affected by inaccurate assumptions OXiGENE might
make or by known or unknown risks and uncertainties, including, but
not limited to: the early stage of product development; the ability to
secure necessary patents; uncertainties as to the future success of
ongoing and planned clinical trials; and the unproven safety and
efficacy of products under development. Consequently, no
forward-looking statement can be guaranteed, and actual results may
vary materially. Additional information concerning factors that could
cause actual results to materially differ from those in the
forward-looking statements is contained in OXiGENE's reports to the
Securities and Exchange Commission, including OXiGENE's Form 10-Q, 8-K
and 10-K reports. However, OXiGENE undertakes no obligation to
publicly update forward-looking statements, whether because of new
information, future events or otherwise.
CONTACT: OXiGENE, Inc.
Investor Relations, +1 781-547-5900
( BW)(MA-OXIGENE)(OXGN)(OXGN.ST) OXiGENE Participates in Cowen & Company 27th Annual Healthcare Conference Available via Webcast
| Source: Oxigene, Inc.
Attachments
